Sagimet Biosciences Inc.
SGMT
$6.30
$0.223.54%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -24.28% | 42.86% | -12.19% | -10.82% | -80.08% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 43.76% | 44.47% | -35.58% | 43.47% | 4.87% |
| Change in Net Operating Assets | 660.80% | -104.69% | -27.25% | 160.97% | -506.64% |
| Cash from Operations | -11.86% | 37.39% | -31.86% | 43.67% | -247.34% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 100.56% | -489.39% | -65.35% | 1,478.53% | 100.83% |
| Cash from Investing | 100.56% | -489.39% | -65.35% | 1,478.53% | 100.83% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 27,300.00% | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | 100.00% |
| Cash from Financing | 27,300.00% | -- | -- | -- | 100.00% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 56.09% | -101.29% | -847.44% | 93.80% | 76.56% |